SCHEMBL16447604

SCHEMBL16447604

Cc1nc2cc(F)ccn2c1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.46
KMT2A Q03164 3/20 0.45
GAA P10253 4/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 3/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
HTT P42858 3/20 0.43
LMNA P02545 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
ALDH1A1 P00352 3/20 0.41
MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL21818304 0.85 GAA (0.45) SMN1; SMN2KMT2AGAAPOLBKDM4E
SCHEMBL1768162 0.84 SMN1; SMN2 (0.61) SMN1; SMN2KMT2AGAAPOLBKDM4E
SCHEMBL16447607 0.81 MAPK1 (0.65) SMN1; SMN2KMT2AGAAPOLBKDM4E
SCHEMBL30770769 0.81 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AGAAPOLBKDM4E
SCHEMBL23109099 0.81 CYP2C9 (0.40) SMN1; SMN2KMT2APOLBKDM4EMEN1
SCHEMBL21893931 0.79 MAPT (0.45) SMN1; SMN2KMT2AGAAPOLBKDM4E
SCHEMBL12294564 0.79 SMN1; SMN2 (0.50) SMN1; SMN2KMT2AGAAKDM4EMAPT
SCHEMBL17876427 0.78 KDM4E (0.58) SMN1; SMN2KMT2AGAAPOLBKDM4E
SCHEMBL9893257 0.78 CYP11B1 (0.49) SMN1; SMN2KMT2AGAAKDM4EMEN1
SCHEMBL27110032 0.78 CGAS (0.54) SMN1; SMN2KMT2APOLBKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed
EP-3027615-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2021-07-21 EP disclosed
WO-2020065613-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-02 WO disclosed
US-20160185774-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2016-06-30 US disclosed
US-20160185774-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2016-06-30 US disclosed
WO-2015014993-A2 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2015-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP SMN1; SMN2 3418/4885KMT2A 1069/4885GAA 94/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP SMN1; SMN2 3418/4885KMT2A 1069/4885GAA 94/4885
US-20160185774-A1 Anti-Infective Compounds RABGGTB, ELANE, SERPINB1 SMN1; SMN2 4839/4885KMT2A 4781/4885GAA 949/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP SMN1; SMN2 3418/4885KMT2A 1069/4885GAA 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.